Qiagen (NASDAQ:QGEN) will announce its earnings results after the market closes on Wednesday, January 31st. Analysts expect the company to announce earnings of $0.41 per share for the quarter. Qiagen has set its Q4 guidance at $0.41-0.42 EPS.
Qiagen (NASDAQ:QGEN) last issued its earnings results on Monday, November 6th. The company reported $0.32 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.32. The firm had revenue of $364.00 million for the quarter, compared to analyst estimates of $363.42 million. Qiagen had a return on equity of 11.36% and a net margin of 6.40%. Qiagen’s revenue for the quarter was up 7.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.29 earnings per share. On average, analysts expect Qiagen to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Shares of Qiagen (NASDAQ QGEN) opened at $34.41 on Tuesday. The company has a market capitalization of $8,010.00, a P/E ratio of 88.23, a P/E/G ratio of 2.01 and a beta of 1.10. Qiagen has a 52-week low of $27.74 and a 52-week high of $36.34. The company has a debt-to-equity ratio of 0.68, a current ratio of 5.33 and a quick ratio of 4.78.
A number of equities research analysts recently commented on QGEN shares. Zacks Investment Research lowered Qiagen from a “buy” rating to a “hold” rating in a research report on Monday, October 16th. Deutsche Bank reiterated a “buy” rating on shares of Qiagen in a research report on Wednesday, November 8th. Cowen reiterated a “hold” rating and issued a $34.00 target price on shares of Qiagen in a research report on Thursday, December 21st. DZ Bank reiterated a “neutral” rating on shares of Qiagen in a research report on Tuesday, December 19th. Finally, TheStreet upgraded Qiagen from a “c+” rating to a “b+” rating in a research report on Tuesday, November 7th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and six have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $35.11.
TRADEMARK VIOLATION WARNING: This article was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/01/30/qiagen-qgen-scheduled-to-post-quarterly-earnings-on-wednesday.html.
Qiagen Company Profile
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.